PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
PharmaTher Explores Hantavirus Treatment Amidst Stock Plunge and Strategic Pivots
The most recent news release (May 13, 2026) announces that Sairiyo Therapeutics Inc., a subsidiary in which PharmaTher holds a 49% equity stake, is exploring its patented reformulated Cepharanthine (PD-001) for the treatment of Hantavirus. Independent research indicates significant inhibition of Hantavirus pseudovirus in mouse models at various dosages. Sairiyo has received ethics approval to initiate a Phase 1 clinical study in healthy volunteers to evaluate safety and bioavailability. The company highlights that PD-001 addresses historical limitations regarding oral bioavailability through an enteric-coated formulation protected by US Patent US10576077 (expiring March 23, 2036). This follows a history of strategic pivots including the sale of a Ketamine ANDA for potential >$25M in proceeds, expansion into GLP-1 and peptide microneedle patches, and support for U.S. regulatory shifts on psychedelics and peptides.
The news is classified as Routine - Neutral because it represents early-stage research development rather than a commercial milestone or financial result. While the independent research data (92-94% inhibition in mice) is scientifically interesting, it does not guarantee clinical success in humans. The Phase 1 study has only received ethics approval; no efficacy or safety results are available yet. Furthermore, PharmaTher owns only 49% of Sairiyo Therapeutics Inc., meaning the financial upside from any future commercialization of PD-001 is diluted for PharmaTher shareholders compared to a wholly-owned asset. Given the company's history of multiple strategic pivots (Ketamine -> Peptides -> GLP-1 -> Hantavirus) and the significant decline in stock price despite previous "positive" announcements regarding the Ketamine ANDA sale, this news does not materially alter the fundamental risk profile or immediate financial outlook. It is a continuation of R&D exploration without near-term revenue impact.
- Company: PharmaTher Holdings Ltd. (Ticker: PHRM).
- Flagship Projects:
- Ketamine Portfolio: Includes the sold ANDA #217858, Long-Acting Injectable (LAI) ketamine program in partnership with Oakwood Laboratories, and proprietary programs for Parkinson's disease (LID-PD), ALS, and CRPS.
- Delivery Platforms: PharmaPatch™ microneedle patches (Ketamine, Psychedelics, GLP-1, Peptides) and PatchPrint™ manufacturing platform.
- Digital Health AI: KetAImine™ discovery platform and KetaVault™ data repository.
- Development Status: The company is transitioning from generic asset monetization to proprietary pipeline development (505(b)(2) pathway). The Hantavirus program is in the earliest clinical phase (Phase 1 approval received, results pending).